SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1740 634X "

Sökning: L773:1740 634X

  • Resultat 61-70 av 156
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  •  
62.
  • Hawes, Jessica, et al. (författare)
  • Galanin Protects Against Behavioral and Neurochemical Correlates of Opiate Reward
  • 2008
  • Ingår i: Neuropsychopharmacology. - : Springer Science and Business Media LLC. - 0893-133X .- 1740-634X. ; 33:8, s. 1864-1873
  • Tidskriftsartikel (refereegranskat)abstract
    • The mechanisms underlying responses to drugs of abuse have been widely investigated; however, less is known about pathways normally protective against the development of drug reinforcement. These pathways are also important since they may regulate individual differences in vulnerability to addiction. The neuropeptide galanin and its binding sites are expressed in brain areas important for drug reward. Previous studies have shown that centrally infused galanin attenuates morphine place preference and peripheral injection of galnon, a galanin agonist, decreases opiate withdrawal signs. The current studies in galanin knockout (GKO) mice examined the hypothesis that galanin is an endogenous negative regulator of opiate reward and identified downstream signaling pathways regulated by galanin. We show that GKO mice demonstrate increased locomotor activation following morphine administration, which is inhibited by acute administration of galnon. GKO mice also show enhanced morphine place preference, supporting the idea that galanin normally antagonizes opiate reward. In addition, morphine-induced ERK1/2 phosphorylation was increased in the VTA of both wild-type and GKO mice, but only the GKO mice showed increases in ERK1/2 and CREB phosphorylation in the amygdala or nucleus accumbens. Furthermore, a single systemic injection of galnon in GKO mice was sufficient to reverse some of the biochemical changes brought about by morphine administration. These data suggest that galanin normally attenuates behavioral and neurochemical effects of opiates; thus, galanin agonists may represent a new class of therapeutic targets for opiate addiction.
  •  
63.
  • Heilig, Markus, et al. (författare)
  • Addiction as a brain disease revised : why it still matters, and the need for consilience
  • 2021
  • Ingår i: Neuropsychopharmacology. - : Springer Nature. - 0893-133X .- 1740-634X. ; 46:10, s. 1715-1723
  • Forskningsöversikt (refereegranskat)abstract
    • The view that substance addiction is a brain disease, although widely accepted in the neuroscience community, has become subject to acerbic criticism in recent years. These criticisms state that the brain disease view is deterministic, fails to account for heterogeneity in remission and recovery, places too much emphasis on a compulsive dimension of addiction, and that a specific neural signature of addiction has not been identified. We acknowledge that some of these criticisms have merit, but assert that the foundational premise that addiction has a neurobiological basis is fundamentally sound. We also emphasize that denying that addiction is a brain disease is a harmful standpoint since it contributes to reducing access to healthcare and treatment, the consequences of which are catastrophic. Here, we therefore address these criticisms, and in doing so provide a contemporary update of the brain disease view of addiction. We provide arguments to support this view, discuss why apparently spontaneous remission does not negate it, and how seemingly compulsive behaviors can co-exist with the sensitivity to alternative reinforcement in addiction. Most importantly, we argue that the brain is the biological substrate from which both addiction and the capacity for behavior change arise, arguing for an intensified neuroscientific study of recovery. More broadly, we propose that these disagreements reveal the need for multidisciplinary research that integrates neuroscientific, behavioral, clinical, and sociocultural perspectives.
  •  
64.
  •  
65.
  •  
66.
  •  
67.
  • Hensch, Tilman, et al. (författare)
  • Further evidence for an association of 5-HTTLPR with intensity dependence of auditory-evoked potentials
  • 2006
  • Ingår i: Neuropsychopharmacology. - : Springer Science and Business Media LLC. - 0893-133X .- 1740-634X. ; 31:9, s. 2047-2054
  • Tidskriftsartikel (refereegranskat)abstract
    • Intensity dependence of auditory-evoked potentials (IAEP) has been suggested as an indicator of central serotonergic neurotransmission. Two recent studies investigated a possible association of IAEP with a functional polymorphism in the transcriptional control region of the serotonin transporter gene (5-HTTLPR) that has a short (s) and a long (l) variant. Although both studies found an association between 5-HTTLPR and IAEP, Gallinat et al found l/l individuals to exhibit lower IAEP, whereas Strobel et al observed stronger IAEP in l/l individuals. These conflicting results require further evaluation and more attention needs to be paid to variables that are known to be confounded with the effects of IAEP and 5-HTTLPR. Using a paradigm comparable to Strobel et al, the present study analyzes the effect of 5-HTTLPR on IAEP in a healthy male student sample (N=91; age=23 years, SD=1.9) that was homogenous for most significant confounding variables. A stronger IAEP was shown in l/l individuals, irrespective of the method of IAEP parametrization. This also held at retest after 3 weeks in a subsample (N=18). Given the successful replication of Strobel et al, several possible reasons for conflicting results with regard to Gallinat et al are discussed. It is argued that the most significant difference between Gallinat et al on the one hand, and Strobel et al and this study on the other, is that different intensity ranges are used which impact IAEP. Therefore, this study encourages further analysis of dose dependence of results.
  •  
68.
  •  
69.
  • Jakobsson, Joel, et al. (författare)
  • Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder
  • 2013
  • Ingår i: Neuropsychopharmacology. - : Springer Science and Business Media LLC. - 0893-133X .- 1740-634X. ; 38:4, s. 664-672
  • Tidskriftsartikel (refereegranskat)abstract
    • Bipolar disorder is a psychiatric disorder characterized by recurrent episodes of mania/hypomania and depression. Progressive cognitive dysfunction such as impairments in executive function and verbal memory is common in euthymic bipolar patients. The cerebrospinal fluid has previously been used to study neurodegenerative processes in Alzheimer’s disease, from which changes in three core biomarkers have emerged as indicative of degeneration: amyloid β, total tau, and hyperphosphorylated tau. Here, neurodegeneration in bipolar disorder was investigated by assessing the association between bipolar disorder and cerebrospinal fluid biomarkers for neurodegenerative processes. Cerebrospinal fluid was obtained from 139 bipolar disorder patients and 71 healthy controls. Concentrations of total and phosphorylated tau, amyloid β1-42, amyloid β38/β40/β42, and the soluble forms of amyloid precursor protein were measured in patients vs controls. The concentrations of the soluble forms of amyloid precursor protein were significantly lower in bipolar patients compared with controls. The amyloid β42/amyloid β38 and the amyloid β42/amyloid β40 ratios were higher in bipolar patients than controls. There were no discernible differences in the concentrations of total/phosphorylated tau, amyloid β1-42, or amyloid β38/β40/β42. The concentrations of the biomarkers within the bipolar patient group were further associated with different ongoing medical treatments and diagnostic subgroups. The findings suggest that the amyloid precursor protein metabolism is altered in bipolar disorder. The results may have implications for the understanding of the pathophysiology of bipolar disorder and for the development of treatment strategies. Importantly, there were no signs of an Alzheimer-like neurodegenerative process among bipolar patients.
  •  
70.
  • Jakobsson, Joel, et al. (författare)
  • Elevated Concentrations of Neurofilament Light Chain in The Cerebrospinal Fluid of Bipolar Disorder Patients.
  • 2014
  • Ingår i: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. - : Springer Science and Business Media LLC. - 1740-634X. ; 39, s. 2349-2356
  • Tidskriftsartikel (refereegranskat)abstract
    • Bipolar disorder (BD) is characterized by mood swings between manic and depressive states. The etiology and pathogenesis of BD is unclear, but many of the affected cognitive domains, as well as neuroanatomical abnormalities, resemble symptoms and signs of small vessel disease. In small vessel disease, cerebrospinal fluid (CSF) markers reflecting damages in different cell types and subcellular structures of the brain have been established. Hence, we hypothesized that CSF markers related to small vessel disease may also be applicable as biomarkers for bipolar disorder. To investigate this hypothesis, we sampled CSF from 133 patients with bipolar disorder and 86 healthy controls. The concentrations of neurofilament light chain (NF-L), myelin basic protein (MBP), S100B, and heart-fatty acid binding protein (H-FABP) were measured in CSF and analyzed in relation to diagnosis, clinical characteristics, and ongoing medications. Hereby we found an elevation of the marker of subcortical axonal damage, NF-L, in bipolar subjects. We also identified positive associations between NF-L and treatment with atypical antipsychotics, MBP and lamotrigine, and H-FABP and lithium. These findings indicate axonal damage as an underlying neuropathological component of bipolar disorder, though the clinical value of elevated NF-L remains to be validated in follow-up studies. The associations between current medications and CSF brain injury markers might aid in the understanding of both therapeutic and adverse effects of these drugs.Neuropsychopharmacology accepted article peview online, 03 April 2014; doi:10.1038/npp.2014.81.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 156
Typ av publikation
tidskriftsartikel (152)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (139)
övrigt vetenskapligt/konstnärligt (17)
Författare/redaktör
Heilig, Markus (12)
Mathe, AA (6)
Eriksson, Elias, 195 ... (5)
Landén, Mikael, 1966 (4)
Ogren, SO (4)
Leggio, Lorenzo (4)
visa fler...
Blennow, Kaj, 1958 (3)
Andreassen, OA (3)
Baune, BT (3)
Stein, DJ (3)
Zetterberg, Henrik, ... (3)
Halldin, C (3)
Heinz, A (3)
Rietschel, M (3)
Adermark, Louise, 19 ... (3)
Söderpalm, Bo, 1959 (3)
Ericson, Mia, 1970 (3)
Li, Q. (2)
Svenningsson, P (2)
Mitchell, PB (2)
Roberts, G (2)
Langel, Ülo (2)
Wikström, Johan, 196 ... (2)
Penninx, BWJH (2)
Abé, C (2)
Benedetti, F (2)
Busatto, GF (2)
Jahanshad, N (2)
Thompson, PM (2)
Radua, J (2)
Fredriksson, I (2)
Ching, CRK (2)
Haukvik, UK (2)
Mattheisen, M (2)
Cichon, S (2)
Erk, S (2)
Lawrie, SM (2)
Meyer-Lindenberg, A (2)
Nothen, MM (2)
Romanczuk-Seiferth, ... (2)
Schofield, PR (2)
Smoller, JW (2)
Sussmann, JE (2)
Walter, H (2)
Dickson, Suzanne L., ... (2)
Jerlhag, Elisabeth, ... (2)
Jokinen, Jussi (2)
Madjid, N (2)
Domi, Ana, 1990 (2)
Girault, JA (2)
visa färre...
Lärosäte
Karolinska Institutet (93)
Linköpings universitet (29)
Göteborgs universitet (21)
Uppsala universitet (17)
Umeå universitet (10)
Stockholms universitet (6)
visa fler...
Lunds universitet (5)
Högskolan Kristianstad (1)
Örebro universitet (1)
Malmö universitet (1)
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (156)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (74)
Samhällsvetenskap (10)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy